Medroxyprogesterone acetate: Risk of meningioma and measures to minimise this risk.

Summary

• There is an increased risk of developing meningioma with high doses of medroxyprogesterone acetate (all injectable and ≥100 mg oral formulations), primarily after prolonged use (several years).
• For contraception or non-oncological indications:
  • Medicines containing high doses medroxyprogesterone acetate are contraindicated in patients with meningioma or a history of meningioma. 
  • If meningioma is diagnosed in a patient treated with high doses medroxyprogesterone acetate, treatment must be stopped. 
• For oncological indications: 
  • If a meningioma is diagnosed in a patient treated with high doses medroxyprogesterone acetate, the need to continue the treatment should be carefully reconsidered, on a case-by-case basis taking into account individual benefits and risks.
• Patients treated with high doses medroxyprogesterone acetate should be monitored for signs and symptoms of meningioma in accordance with clinical practice.